Adult Dosing
- Therapy is not indicated in adults
Pediatric Dosing
Acute lymphoblastic leukemia
Note: Several regimens have been used. Please refer to institution protocols/references
- 165 mg/m2 twice weekly for 8–9 doses
Alternative
- 250 mg/m2 q wk x 4–8 wk
- Decrease initial dose 50% in pts w/ Down Syndrome
[Outline]
- Administer teniposide only under supervision of physician experienced in cancer chemotherapy in adequate medical facility to manage complications [US Black Box Warning]
- Severe myelosuppression may cause infection or bleeding also hypersensitivity reactions may occur with initial dosing or repeated exposure [US Black Box Warning]
- Therapy should be given only by slow intravenous infusion (lasting at least 30 to 60 minutes) to avoid hypotension as a possible side effect. Discontinue therapy if hypotension occur
- Therapy may cause fetal harm when administered to a pregnant woman; patient should be apprised of the potential hazard to the fetus if therapy is used during pregnancy, or if the patient becomes pregnant while receiving this drug
- Prior to initiating therapy, need and usefulness of the drug against the risk of adverse reactions should be evaluated
- Prior to infusion care should be taken to ensure that the intravenous catheter or needle is in the proper position and functional
Cautions: Use cautiously in
- Renal impairment
- Hepatic impairment
Pregnancy Category:D
Breastfeeding: Safety Unknown. Due to the potential for serious adverse reactions in nursing infants, manufacturer recommends discontinuation of nursing or discontinuation of drug, taking into account the importance of the drug to the mother.
